Domingo Francisco Javier DÃ-ez MartÃ

List of Publications by Year
in descending order

308 papers	19,354 citations	8755 77 h-index	17891 125 g-index
326 all docs	326 docs citations	326 times ranked	21072 citing authors

#	Article	IF	Citations
1	Myocardial remodeling after infarction: the role of myofibroblasts. Nature Reviews Cardiology, 2010, 7, 30-37.	6.1	612
2	Losartan-Dependent Regression of Myocardial Fibrosis Is Associated With Reduction of Left Ventricular Chamber Stiffness in Hypertensive Patients. Circulation, 2002, 105, 2512-2517.	1.6	572
3	Myocardial Fibrosis as an Early Manifestation of Hypertrophic Cardiomyopathy. New England Journal of Medicine, 2010, 363, 552-563.	13.9	566
4	Myocardial Interstitial Fibrosis in HeartÂFailure. Journal of the American College of Cardiology, 2018, 71, 1696-1706.	1.2	406
5	Increased Collagen Type I Synthesis in Patients With Heart Failure of Hypertensive Origin. Circulation, 2004, 110, 1263-1268.	1.6	392
6	New strategies for heart failure with preserved ejection fraction: the importance of targeted therapies for heart failure phenotypes. European Heart Journal, 2014, 35, 2797-2815.	1.0	304
7	Prevalence of Left Ventricular Diastolic Dysfunction in a General Population. Circulation: Heart Failure, 2009, 2, 105-112.	1.6	291
8	Myocardial fibrosis: biomedical research from bench to bedside. European Journal of Heart Failure, 2017, 19, 177-191.	2.9	280
9	Reverse Myocardial Remodeling FollowingÂValve Replacement in PatientsÂWith Aortic Stenosis. Journal of the American College of Cardiology, 2018, 71, 860-871.	1.2	266
10	Effects of loop diuretics on myocardial fibrosis and collagen type I turnover in chronic heart failure. Journal of the American College of Cardiology, 2004, 43, 2028-2035.	1.2	248
11	Usefulness of Serum Carboxy-Terminal Propeptide of Procollagen Type I in Assessment of the Cardioreparative Ability of Antihypertensive Treatment in Hypertensive Patients. Circulation, 2001, 104, 286-291.	1.6	244
12	Myocardial Titin Hypophosphorylation Importantly Contributes to Heart Failure With Preserved Ejection Fraction in a Rat Metabolic Risk Model. Circulation: Heart Failure, 2013, 6, 1239-1249.	1.6	241
13	Torasemide in chronic heart failure: results of the TORIC study. European Journal of Heart Failure, 2002, 4, 507-513.	2.9	215
14	Alterations in the Pattern of Collagen Deposition May Contribute to the Deterioration of Systolic Function in Hypertensive Patients With Heart Failure. Journal of the American College of Cardiology, 2006, 48, 89-96.	1.2	214
15	Role of lysyl oxidase in myocardial fibrosis: from basic science to clinical aspects. American Journal of Physiology - Heart and Circulatory Physiology, 2010, 299, H1-H9.	1.5	209
16	The relevance of tissue angiotensin-converting enzyme: manifestations in mechanistic and endpoint data. American Journal of Cardiology, 2001, 88, 1-20.	0.7	202
17	Circulating Biomarkers of Myocardial Fibrosis. Journal of the American College of Cardiology, 2015, 65, 2449-2456.	1.2	196
18	Circulating Biomarkers of Collagen Metabolism in Cardiac Diseases. Circulation, 2010, 121, 1645-1654.	1.6	195

#	Article	IF	Citations
19	T1 Measurements Identify Extracellular Volume Expansion in Hypertrophic Cardiomyopathy Sarcomere Mutation Carriers With and Without Left Ventricular Hypertrophy. Circulation: Cardiovascular Imaging, 2013, 6, 415-422.	1.3	195
20	Targeting LOXL2 for cardiac interstitial fibrosis and heart failure treatment. Nature Communications, 2016, 7, 13710.	5.8	190
21	Mechanisms of Cardiac Fibrosis in Hypertension. Journal of Clinical Hypertension, 2007, 9, 546-550.	1.0	183
22	Towards better definition, quantification and treatment of fibrosis in heart failure. A scientific roadmap by the Committee of Translational Research of the Heart Failure Association (HFA) of the European Society of Cardiology. European Journal of Heart Failure, 2019, 21, 272-285.	2.9	182
23	Reappraising myocardial fibrosis in severe aortic stenosis: an invasive and non-invasive study in 133 patients. European Heart Journal, 2018, 39, 699-709.	1.0	178
24	Surrogate Markers for Cardiovascular Disease: Structural Markers. Circulation, 2004, 109, IV-22-IV-30.	1.6	175
25	Myocardial Fibrosis Quantified by Extracellular Volume Is Associated With Subsequent Hospitalization for Heart Failure, Death, or Both Across the Spectrum of Ejection Fraction and Heart Failure Stage. Journal of the American Heart Association, 2015, 4, .	1.6	174
26	Collagen Cross-Linking But Not Collagen Amount Associates With Elevated Filling Pressures in Hypertensive Patients With Stage C Heart Failure. Hypertension, 2012, 60, 677-683.	1.3	170
27	C-Reactive Protein Induces Matrix Metalloproteinase-1 and -10 in Human Endothelial Cells. Journal of the American College of Cardiology, 2006, 47, 1369-1378.	1.2	168
28	Temporal Relation Between Myocardial Fibrosis and Heart Failure With Preserved Ejection Fraction. JAMA Cardiology, 2017, 2, 995.	3.0	164
29	Immunohistochemical detection of chloride/bicarbonate anion exchangers in human liver. Hepatology, 1994, 19, 1400-1406.	3.6	159
30	Biochemical Assessment of Myocardial Fibrosis in Hypertensive Heart Disease. Hypertension, 2001, 38, 1222-1226.	1.3	157
31	Different Effects of Antihypertensive Therapies Based on Losartan or Atenolol on Ultrasound and Biochemical Markers of Myocardial Fibrosis. Circulation, 2004, 110, 552-557.	1.6	157
32	New Targets to Treat the Structural Remodeling of the Myocardium. Journal of the American College of Cardiology, 2011, 58, 1833-1843.	1.2	147
33	Impact of Treatment on Myocardial Lysyl Oxidase Expression and Collagen Cross-Linking in Patients With Heart Failure. Hypertension, 2009, 53, 236-242.	1.3	144
34	Mechanisms of Disease: pathologic structural remodeling is more than adaptive hypertrophy in hypertensive heart disease. Nature Clinical Practice Cardiovascular Medicine, 2005, 2, 209-216.	3.3	143
35	Diltiazem Treatment for Pre-Clinical Hypertrophic Cardiomyopathy SarcomereÂMutation Carriers. JACC: Heart Failure, 2015, 3, 180-188.	1.9	137
36	Abnormal expression of anion exchanger genes in primary biliary cirrhosis. Gastroenterology, 1993, 105, 572-578.	0.6	132

#	Article	IF	Citations
37	Oxidative stress and vascular remodelling. Experimental Physiology, 2005, 90, 457-462.	0.9	129
38	MicroRNA-221/222 Family Counteracts Myocardial Fibrosis in Pressure Overloadâ€“Induced Heart Failure. Hypertension, 2018, 71, 280-288.	1.3	128
39	Diffuse myocardial fibrosis: mechanisms, diagnosis and therapeutic approaches. Nature Reviews Cardiology, 2021, 18, 479-498.	6.1	128
40	Myocardial Collagen Cross-Linking IsÂAssociated With Heart Failure Hospitalization in Patients With Hypertensive Heart Failure. Journal of the American College of Cardiology, 2016, 67, 251-260.	1.2	127
41	Myocardial Remodeling in Hypertension. Hypertension, 2018, 72, 549-558.	1.3	123
42	Phagocytic NADPH Oxidase Overactivity Underlies Oxidative Stress in Metabolic Syndrome. Diabetes, 2006, 55, 209-215.	0.3	121
43	Effects of loop diuretics on angiotensin IIâ€stimulated vascular smooth muscle cell growth. Nephrology Dialysis Transplantation, 2001, 16, 14-17.	0.4	118
44	Pathophysiologic and therapeutic importance of tissue ACE: a consensus report. Cardiovascular Drugs and Therapy, 2002, 16, 149-160.	1.3	118
45	Identification of a Potential Cardiac Antifibrotic Mechanism of Torasemide in Patients With Chronic Heart Failure. Journal of the American College of Cardiology, 2007, 50, 859-867.	1.2	118
46	Clinical aspects of hypertensive myocardial fibrosis. Current Opinion in Cardiology, 2001, 16, 328-335.	0.8	116
47	Osteopontin-mediated myocardial fibrosis in heart failure: a role for lysyl oxidase?. Cardiovascular Research, 2013, 99, 111-120.	1.8	113
48	Losartan inhibits the post-transcriptional synthesis of collagen type I and reverses left ventricular fibrosis in spontaneously hypertensive rats. Journal of Hypertension, 1999, 17, 107-114.	0.3	111
49	Cardiomyocyte apoptosis in hypertensive cardiomyopathy. Cardiovascular Research, 2003, 59, 549-562.	1.8	110
50	The Inhibitory Effect of Leptin on Angiotensin II-Induced Vasoconstriction in Vascular Smooth Muscle Cells Is Mediated via a Nitric Oxide-Dependent Mechanism. Endocrinology, 2007, 148, 324-331.	1.4	110
51	Searching for new mechanisms of myocardial fibrosis with diagnostic and/or therapeutic potential. European Journal of Heart Failure, 2015, 17, 764-771.	2.9	109
52	Effects of losartan and atenolol on left ventricular mass and neurohormonal profile in patients with essential hypertension and left ventricular hypertrophy. Journal of Hypertension, 2002, 20, 1855-1864.	0.3	107
53	Regulation of Myocardial Fibrillar Collagen by Angiotensin II. A Role in Hypertensive Heart Disease?. Journal of Molecular and Cellular Cardiology, 2002, 34, 1585-1593.	0.9	106
54	Stimulation of Cardiac Apoptosis in Essential Hypertension. Hypertension, 2002, 39, 75-80.	1.3	102

#	Article	IF	Citations
55	Vascular oxidant stress: Molecular mechanisms and pathophysiological implications. Journal of Physiology and Biochemistry, 2000, 56, 57-64.	1.3	101
56	Filling Pressures and Collagen Metabolism in Hypertensive Patients With Heart Failure and Normal Ejection Fraction. Hypertension, 2010, 55, 1418-1424.	1.3	100
57	G Proteinâ€“Coupled Receptor Kinase 2 Plays a Relevant Role in Insulin Resistance and Obesity. Diabetes, 2010, 59, 2407-2417.	0.3	99
58	A Translational Approach to Hypertensive Heart Disease. Hypertension, 2010, 55, 1-8.	1.3	98
59	Leptin Inhibits Angiotensin II-Induced Intracellular Calcium Increase and Vasoconstriction in the Rat Aorta. Endocrinology, 2002, 143, 3555-3560.	1.4	97
60	Cardioprotective Effect of the Mitochondrial Unfolded Protein Response During Chronic Pressure Overload. Journal of the American College of Cardiology, 2019, 73, 1795-1806.	1.2	97
61	Myocardial fibrosis and diastolic dysfunction in patients with hypertension: results from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation versus Atenolol (SILVHIA). Journal of Hypertension, 2007, 25, 1958-1966.	0.3	95
62	GLP-1 and cardioprotection: from bench to bedside. Cardiovascular Research, 2012, 94, 316-323.	1.8	93
63	Association of increased phagocytic NADPH oxidase-dependent superoxide production with diminished nitric oxide generation in essential hypertension. Journal of Hypertension, 2004, 22, 2169-2175.	0.3	92
64	Chronic heart failure as a state of reduced effectiveness of the natriuretic peptide system: implications for therapy. European Journal of Heart Failure, 2017, 19, 167-176.	2.9	91
65	NADPH oxidase CYBA polymorphisms, oxidative stress and cardiovascular diseases. Clinical Science, 2008, 114, 173-182.	1.8	90
66	Epicardial delivery of collagen patches with adipose-derived stem cells in rat and minipig models of chronic myocardial infarction. Biomaterials, 2014, 35, 143-151.	5.7	90
67	Functional Effect of the p22 phox â”930 A/G Polymorphism on p22 phox Expression and NADPH Oxidase Activity in Hypertension. Hypertension, 2004, 44, 163-169.	1.3	89
68	A synthetic peptide from transforming growth factor-Â1 type III receptor prevents myocardial fibrosis in spontaneously hypertensive rats. Cardiovascular Research, 2008, 81, 601-609.	1.8	89
69	Preliminary characterisation of the promoter of the human p22phox gene: identification of a new polymorphism associated with hypertension. FEBS Letters, 2003, 542, 27-31.	1.3	86
70	NADPH Oxidase-Mediated Oxidative Stress: Genetic Studies of thep22phoxGene in Hypertension. Antioxidants and Redox Signaling, 2005, 7, 1327-1336.	2.5	86
71	Sex Dimorphism in the MyocardialÂResponse to Aortic Stenosis. JACC: Cardiovascular Imaging, 2018, 11, 962-973.	2.3	85
72	Fibrosis in hypertensive heart disease: role of the renin-angiotensin-aldosterone system. Medical Clinics of North America, 2004, 88, 83-97.	1.1	83

#	Article	IF	Citations
73	The C242T CYBA polymorphism of NADPH oxidase is associated with essential hypertension. Journal of Hypertension, 2006, 24, 1299-1306.	0.3	83
74	Phagocytic NADPH Oxidase-Dependent Superoxide Production Stimulates Matrix Metalloproteinase-9. Arteriosclerosis, Thrombosis, and Vascular Biology, 2007, 27, 587-593.	1.1	82
75	AT₁receptor antagonism attenuates target organ effects of salt excess in SHRs without affecting pressure. American Journal of Physiology - Heart and Circulatory Physiology, 2008, 294, H853-H858.	1.5	82
76	microRNA-122 down-regulation may play a role in severe myocardial fibrosis in human aortic stenosis through TGF-Î²1 up-regulation. Clinical Science, 2014, 126, 497-506.	1.8	80
77	CT-1 (Cardiotrophin-1)-Gal-3 (Galectin-3) Axis in Cardiac Fibrosis and Inflammation. Hypertension, 2019, 73, 602-611.	1.3	78
78	The effect of spironolactone on cardiovascular function and markers of fibrosis in people at increased risk of developing heart failure: the heart â€˜OMicsâ€™ in AGEing (HOMAGE) randomized clinical trial. European Heart Journal, 2021, 42, 684-696.	1.0	77
79	A random comparison of fosinopril and nifedipine GITS in patients with primary renal disease. Journal of Hypertension, 2001, 19, 1871-1876.	0.3	76
80	Biochemical markers of myocardial remodelling in hypertensive heart disease. Cardiovascular Research, 2008, 81, 509-518.	1.8	73
81	Is plasma cardiotrophin-1 a marker of hypertensive heart disease?. Journal of Hypertension, 2005, 23, 625-632.	0.3	72
82	Arterial Stiffness and Extracellular Matrix. , 2006, 44, 76-95.		71
83	Myocardial fibrosis, impaired coronary hemodynamics, and biventricular dysfunction in salt-loaded SHR. American Journal of Physiology - Heart and Circulatory Physiology, 2006, 290, H1503-H1509.	1.5	70
84	Antiapoptotic effects of GLP-1 in murine HL-1 cardiomyocytes. American Journal of Physiology - Heart and Circulatory Physiology, 2011, 300, H1361-H1372.	1.5	70
85	Ultrasonic Backscatter and Serum Marker of Cardiac Fibrosis in Hypertensives. Hypertension, 2002, 39, 923-928.	1.3	68
86	Oxidative stress and atherosclerosis in early chronic kidney disease. Nephrology Dialysis Transplantation, 2006, 21, 2686-2690.	0.4	68
87	Prevalence of left ventricular diastolic dysfunction in European populations based on cross-validated diagnostic thresholds. Cardiovascular Ultrasound, 2012, 10, 10.	0.5	68
88	The use of collagen-derived serum peptides for the clinical assessment of hypertensive heart disease. Journal of Hypertension, 2005, 23, 1445-1451.	0.3	65
89	Oxidative Stress, Endothelial Dysfunction and Cerebrovascular Disease. Cerebrovascular Diseases, 2007, 24, 24-29.	0.8	65
90	Apoptosis in hypertensive heart disease. Current Opinion in Cardiology, 1998, 13, 317-326.	0.8	64

#	Article	IF	Citations
91	Cardiotrophin-1 is expressed in adipose tissue and upregulated in the metabolic syndrome. American Journal of Physiology - Endocrinology and Metabolism, 2008, 294, E52-E60.	1.8	64
92	Hypertensive left ventricular hypertrophy risk: beyond adaptive cardiomyocytic hypertrophy. Journal of Hypertension, 2011, 29, 17-26.	0.3	64
93	Biomarkerâ€based phenotyping of myocardial fibrosis identifies patients with heart failure with preserved ejection fraction resistant to the beneficial effects of spironolactone: results from the Aldoâ€DHF trial. European Journal of Heart Failure, 2018, 20, 1290-1299.	2.9	64
94	Proteomic Bioprofiles and Mechanistic Pathways of Progression to Heart Failure. Circulation: Heart Failure, 2019, 12, e005897.	1.6	63
95	Myocardial Interstitial Fibrosis in Nonischemic Heart Disease, Part 3/4. Journal of the American College of Cardiology, 2020, 75, 2204-2218.	1.2	63
96	NADPH Oxidaseâ€“Dependent Superoxide Production Is Associated With Carotid Intima-Media Thickness in Subjects Free of Clinical Atherosclerotic Disease. Arteriosclerosis, Thrombosis, and Vascular Biology, 2005, 25, 1452-1457.	1.1	62
97	Losartan Metabolite EXP3179 Blocks NADPH Oxidase-Mediated Superoxide Production by Inhibiting Protein Kinase C. Hypertension, 2009, 54, 744-750.	1.3	62
98	Mechanisms of Increased Susceptibility to Angiotensin IIâ€“Induced Apoptosis in Ventricular Cardiomyocytes of Spontaneously Hypertensive Rats. Hypertension, 2000, 36, 1065-1071.	1.3	59
99	Phenotyping of myocardial fibrosis in hypertensive patients with heart failure. Influence on clinical outcome. Journal of Hypertension, 2017, 35, 853-861.	0.3	58
100	A role for cardiotrophin-1 in myocardial remodeling induced by aldosterone. American Journal of Physiology - Heart and Circulatory Physiology, 2011, 301, H2372-H2382.	1.5	56
101	Increased CD74 expression in human atherosclerotic plaques: contribution to inflammatory responses in vascular cells. Cardiovascular Research, 2009, 83, 586-594.	1.8	55
102	Cardiotrophin 1 Is Involved in Cardiac, Vascular, and Renal Fibrosis and Dysfunction. Hypertension, 2012, 60, 563-573.	1.3	55
103	Myocardial fibrosis in chronic kidney disease: potential benefits of torasemide. Kidney International, 2008, 74, S19-S23.	2.6	54
104	Galectinâ€3 and histological, molecular and biochemical aspects of myocardial fibrosis in heart failure of hypertensive origin. European Journal of Heart Failure, 2015, 17, 385-392.	2.9	54
105	Combination of Circulating Type I Collagen-Related Biomarkers Is AssociatedÂWith AtrialÂFibrillation. Journal of the American College of Cardiology, 2019, 73, 1398-1410.	1.2	54
106	Association Between Left Ventricular Mass and Telomere Length in a Population Study. American Journal of Epidemiology, 2010, 172, 440-450.	1.6	53
107	The Interleukin-1 Axis and Risk of Death inÂPatients With Acutely DecompensatedÂHeart Failure. Journal of the American College of Cardiology, 2019, 73, 1016-1025.	1.2	52
108	Molecular Mechanisms of Atherosclerosis in Metabolic Syndrome. Arteriosclerosis, Thrombosis, and Vascular Biology, 2008, 28, 2187-2194.	1.1	51

#	Article	IF	Citations
109	â€œTargeting the Heartâ€•in Heart Failure. JACC: Heart Failure, 2015, 3, 661-669.	1.9	50
110	The complex dynamics of myocardial interstitial fibrosis in heart failure. Focus on collagen cross-linking. Biochimica Et Biophysica Acta - Molecular Cell Research, 2019, 1866, 1421-1432.	1.9	50
111	Telomere dysfunction in hypertension. Journal of Hypertension, 2007, 25, 2185-2192.	0.3	49
112	Association of Cardiotrophin-1 With Myocardial Fibrosis in Hypertensive Patients With Heart Failure. Hypertension, 2014, 63, 483-489.	1.3	48
113	Natural Compound Library Screening Identifies New Molecules for the Treatment of Cardiac Fibrosis and Diastolic Dysfunction. Circulation, 2020, 141, 751-767.	1.6	48
114	The loop diuretic torasemide interferes with endothelinâ€1 actions in the aorta of hypertensive rats. Nephrology Dialysis Transplantation, 2001, 16, 18-21.	0.4	47
115	Is the balance between nitric oxide and superoxide altered in spontaneously hypertensive rats with endothelial dysfunction?. Nephrology Dialysis Transplantation, 2001, 16, 2-5.	0.4	46
116	Altered cardiac expression of peroxisome proliferator-activated receptor-isoforms in patients with hypertensive heart disease. Cardiovascular Research, 2006, 69, 899-907.	1.8	46
117	Proteomic and Mechanistic Analysis of Spironolactone in Patients at Risk for HF. JACC: Heart Failure, 2021, 9, 268-277.	1.9	46
118	Clinical implications of apoptosis in hypertensive heart disease. American Journal of Physiology - Heart and Circulatory Physiology, 2003, 284, H1495-H1506.	1.5	45
119	Increased phagocytic nicotinamide adenine dinucleotide phosphate oxidaseâ€“dependent superoxide production in patients with early chronic kidney disease. Kidney International, 2005, 68, S71-S75.	2.6	45
120	Characterization of the protective effects of cardiotrophin-1 against non-ischemic death stimuli in adult cardiomyocytes. Cytokine, 2005, 30, 282-292.	1.4	45
121	Association of plasma cardiotrophin-1 with stage C heart failure in hypertensive patients: Potential diagnostic implications. Journal of Hypertension, 2009, 27, 418-424.	0.3	45
122	Role of Cardiac Lymphatics in MyocardialÂEdema and Fibrosis. Journal of the American College of Cardiology, 2020, 76, 735-744.	1.2	45
123	Quinapril decreases myocardial accumulation of extracellular matrix components in spontaneously hypertensive rats. American Journal of Hypertension, 1995, 8, 815-822.	1.0	44
124	Association of Increased Plasma Cardiotrophin-1 With Inappropriate Left Ventricular Mass in Essential Hypertension. Hypertension, 2007, 50, 977-983.	1.3	44
125	Association of depressed cardiac gp130-mediated antiapoptotic pathways with stimulated cardiomyocyte apoptosis in hypertensive patients with heart failure. Journal of Hypertension, 2007, 25, 2148-2157.	0.3	44
126	Is leptin involved in phagocytic NADPH oxidase overactivity in obesity? Potential clinical implications. Journal of Hypertension, 2010, 28, 1944-1950.	0.3	44

#	Article	IF	Citations
127	Differential hypertrophic effects of cardiotrophin-1 on adult cardiomyocytes from normotensive and spontaneously hypertensive rats. Journal of Molecular and Cellular Cardiology, 2006, 41, 902-913.	0.9	43
128	Usefulness of plasma cardiotrophin-1 in assessment of left ventricular hypertrophy regression in hypertensive patients. Journal of Hypertension, 2005, 23, 2297-2304.	0.3	42
129	Monocyte cyclooxygenase-2 overactivity: a new marker of subclinical atherosclerosis in asymptomatic subjects with cardiovascular risk factors?. European Heart Journal, 2005, 26, 153-158.	1.0	42
130	HIF-1-mediated up-regulation of cardiotrophin-1 is involved in the survival response of cardiomyocytes to hypoxia. Cardiovascular Research, 2011, 92, 247-255.	1.8	42
131	Absence of Cardiotrophin 1 Is Associated With Decreased Age-Dependent Arterial Stiffness and Increased Longevity in Mice. Hypertension, 2013, 61, 120-129.	1.3	42
132	Immunomodulation by adoptive regulatory Tâ€cell transfer improves Coxsackievirus B3â€induced myocarditis. FASEB Journal, 2018, 32, 6066-6078.	0.2	42
133	Fibrosis. Journal of the American College of Cardiology, 2008, 52, 2029-2031.	1.2	41
134	Risk for Incident Heart Failure: A Subjectâ€Level Metaâ€Analysis From the Heart â€œOMicsâ€in AGEing (HOMAGE) Study. Journal of the American Heart Association, 2017, 6, .	1.6	41
135	Circulating Long Noncoding RNA LIPCAR Predicts Heart Failure Outcomes in Patients Without Chronic Kidney Disease. Hypertension, 2019, 73, 820-828.	1.3	41
136	Role of matrix metalloproteinases in hypertension-associated cardiac fibrosis. Current Opinion in Nephrology and Hypertension, 2004, 13, 197-204.	1.0	40
137	Insulin-induced NADPH oxidase activation promotes proliferation and matrix metalloproteinase activation in monocytes/macrophages. Free Radical Biology and Medicine, 2009, 46, 1058-1067.	1.3	40
138	Treatment With Lisinopril Normalizes Serum Concentrations of Procollagen Type III Amino-Terminal Peptide in Patients With Essential Hypertension. American Journal of Hypertension, 1994, 7, 52-58.	1.0	39
139	Aldosterone Induces Cardiotrophin-1 Expression in HL-1 Adult Cardiomyocytes. Endocrinology, 2008, 149, 4970-4978.	1.4	39
140	MicroRNA-19b is a potential biomarker of increased myocardial collagen cross-linking in patients with aortic stenosis and heart failure. Scientific Reports, 2017, 7, 40696.	1.6	39
141	Osteoglycin prevents the development of age-related diastolic dysfunction during pressure overload by reducing cardiac fibrosis and inflammation. Matrix Biology, 2018, 66, 110-124.	1.5	39
142	Downregulation of G protein-coupled receptor kinase 2 levels enhances cardiac insulin sensitivity and switches on cardioprotective gene expression patterns. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2014, 1842, 2448-2456.	1.8	38
143	The inhibitory effect of leptin on angiotensin II-induced vasoconstriction is blunted in spontaneously hypertensive rats. Journal of Hypertension, 2006, 24, 1589-1597.	0.3	37
144	Upregulation of myocardial Annexin A5 in hypertensive heart disease: association with systolic dysfunction. European Heart Journal, 2007, 28, 2785-2791.	1.0	37

#	Article	IF	Citations
145	Serum levels of matrix metalloproteinase-10 are associated with the severity of atherosclerosis in patients with chronic kidney disease. Kidney International, 2010, 78, 1275-1280.	2.6	37
146	Cartilage intermediate layer protein 1 (CILP1): A novel mediator of cardiac extracellular matrix remodelling. Scientific Reports, 2017, 7, 16042.	1.6	37
147	Urinary peptides in heart failure: a link to molecular pathophysiology. European Journal of Heart Failure, 2021, 23, 1875-1887.	2.9	37
148	Loss of myocardial LIF receptor in experimental heart failure reduces cardiotrophin-1 cytoprotection. A role for neurohumoral agonists?. Cardiovascular Research, 2007, 75, 536-545.	1.8	36
149	Towards a New Paradigm About Hypertensive Heart Disease. Medical Clinics of North America, 2009, 93, 637-645.	1.1	36
150	A novel CYBA variant, the â€“675A/T polymorphism, is associated with essential hypertension. Journal of Hypertension, 2007, 25, 1620-1626.	0.3	34
151	The combination of carboxyâ€terminal propeptide of procollagen type I blood levels and late gadolinium enhancement at cardiac magnetic resonance provides additional prognostic information in idiopathic dilated cardiomyopathyÂâ€“ÂA multilevel assessment of myocardial fibrosis in dilated cardiomyopathy. European Journal of Heart Failure, 2021, 23, 933-944.	2.9	34
152	Blood pressure control in patients with chronic renal insufficiency in Spain: a cross-sectional study. Journal of Hypertension, 2006, 24, 395-402.	0.3	33
153	The Proinflammatory Mediator CD40 Ligand Is Increased in the Metabolic Syndrome and Modulated by Adiponectin. Journal of Clinical Endocrinology and Metabolism, 2008, 93, 2319-2327.	1.8	33
154	Biomarkers of cardiomyocyte injury and stress identify left atrial and left ventricular remodelling and dysfunction: A population-based study. International Journal of Cardiology, 2015, 185, 177-185.	0.8	31
155	Association of cystatin C with heart failure with preserved ejection fraction in elderly hypertensive patients. Journal of Hypertension, 2016, 34, 130-138.	0.3	30
156	Sacubitril-Valsartan, Clinical Benefits and Related Mechanisms of Action in Heart Failure With Reduced Ejection Fraction. A Review. Frontiers in Cardiovascular Medicine, 2021, 8, 754499.	1.1	30
157	Review of the molecular pharmacology of Losartan and its possible relevance to stroke prevention in patients with hypertension. Clinical Therapeutics, 2006, 28, 832-848.	1.1	29
158	Investigating a biomarkerâ€driven approach to target collagen turnover in diabetic heart failure with preserved ejection fraction patients. Effect of torasemide versus furosemide on serum Câ€terminal propeptide of procollagen type I (DROPâ€PIP trial). European Journal of Heart Failure, 2018, 20, 460-470.	2.9	29
159	Insulin-like growth factor I in essential hypertension. Kidney International, 1999, 55, 744-759.	2.6	28
160	Ultrasonic Backscatter and Diastolic Function in Hypertensive Patients. Hypertension, 2002, 40, 239-243.	1.3	28
161	Independent Association of Fibrinogen with Carotid Intima-Media Thickness in Asymptomatic Subjects. Cerebrovascular Diseases, 2003, 16, 356-362.	0.8	28
162	Potential spironolactone effects on collagen metabolism biomarkers in patients with uncontrolled blood pressure. Heart, 2019, 105, 307-314.	1.2	28

#	Article	IF	Citations
163	Galectin-3 Inhibition With Modified Citrus Pectin in Hypertension. JACC Basic To Translational Science, 2021, 6, 12-21.	1.9	28
164	Vascular effects of cardiotrophin-1: a role in hypertension?. Journal of Hypertension, 2010, 28, 1261-1272.	0.3	28
165	Impact of collagen type I turnover on the long-term response to cardiac resynchronization therapy. European Heart Journal, 2008, 29, 898-906.	1.0	27
166	Association of low GLP-1 with oxidative stress is related to cardiac disease and outcome in patients with type 2 diabetes mellitus: A pilot study. Free Radical Biology and Medicine, 2015, 81, 1-12.	1.3	27
167	Cardiotrophin-1 plasma levels are associated with the severity of hypertrophy in hypertrophic cardiomyopathy. European Heart Journal, 2011, 32, 177-183.	1.0	26
168	Biomarkers of collagen type I metabolism are related to B-type natriuretic peptide, left ventricular size, and diastolic function in heart failure. Journal of Cardiovascular Medicine, 2014, 15, 463-469.	0.6	26
169	Papel del colÃ¡geno miocÃ¡rdico en la estenosis aÃ³rtica grave conÂfracciÃ³n deÂeyecciÃ³n conservada yÂsÃntomas deÂinsuficiencia cardiaca. Revista Espanola De Cardiologia, 2017, 70, 832-840.	0.6	26
170	Transitioning from usual care to biomarker-based personalized and precision medicine in heart failure: call for action. European Heart Journal, 2018, 39, 2793-2799.	1.0	26
171	Cardiac resynchronization therapy-induced left ventricular reverse remodelling is associated with reduced plasma annexin A5. Cardiovascular Research, 2010, 88, 304-313.	1.8	25
172	Serelaxin: A Novel Therapy for Acute Heart Failure with a Range of Hemodynamic and Non-Hemodynamic Actions. American Journal of Cardiovascular Drugs, 2014, 14, 275-285.	1.0	25
173	Angiotensin Converting Enzyme Inhibition Corrects Na+/H+ Exchanger Overactivity in Essential Hypertension. American Journal of Hypertension, 1997, 10, 84-93.	1.0	24
174	The activity of circulating dipeptidyl peptidase-4 is associated with subclinical left ventricular dysfunction in patients with type 2 diabetes mellitus. Cardiovascular Diabetology, 2013, 12, 143.	2.7	24
175	A Urinary Fragment of Mucin-1 Subunit Î± Is a Novel Biomarker Associated With Renal Dysfunction in the General Population. Kidney International Reports, 2017, 2, 811-820.	0.4	24
176	Usefulness of Collagen Carboxy-Terminal Propeptide and Telopeptide to Predict Disturbances of Long-Term Mortality in Patients â‰¥60ÂYears With Heart Failure and Reduced Ejection Fraction. American Journal of Cardiology, 2017, 119, 2042-2048.	0.7	24
177	Heart â€˜omicsâ€™ in AGEing (HOMAGE): design, research objectives and characteristics of the common database. Journal of Biomedical Research, 2014, 28, 349.	0.7	24
178	Apoptosis in hypertensive heart disease: a clinical approach. Current Opinion in Cardiology, 2006, 21, 288-294.	0.8	23
179	Management of cardiac fibrosis is the largest unmet medical need in heart failure. Cardiovascular Research, 2022, 118, e20-e22.	1.8	23
180	Serum Soluble ST2 as a Biochemical Marker of Acute Heart Failure. Journal of the American College of Cardiology, 2008, 52, 1466-1467.	1.2	22

#	Article	IF	Citations
181	Cardiotrophin-1 induces sarcoplasmic reticulum Ca2+ leak and arrhythmogenesis in adult rat ventricular myocytes. Cardiovascular Research, 2012, 96, 81-89.	1.8	22
182	Cardiotrophin-1 in hypertensive heart disease. Endocrine, 2012, 42, 9-17.	1.1	22
183	Biomarkers of cardiovascular stress and fibrosis in preclinical hypertrophic cardiomyopathy. Open Heart, 2017, 4, e000615.	0.9	22
184	Diastolic Left Ventricular Function in Relation to Urinary and Serum Collagen Biomarkers in a General Population. PLoS ONE, 2016, 11, e0167582.	1.1	22
185	Profibrotic Effects of Angiotensin II in the Heart. Hypertension, 2004, 43, 1164-1165.	1.3	21
186	A Synthetic Peptide from Transforming Growth Factor-Î²₁Type III Receptor Inhibits NADPH Oxidase and Prevents Oxidative Stress in the Kidney of Spontaneously Hypertensive Rats. Antioxidants and Redox Signaling, 2013, 19, 1607-1618.	2.5	21
187	Serelaxin for the treatment of acute heart failure: a review with a focus on end-organ protection. European Heart Journal - Cardiovascular Pharmacotherapy, 2016, 2, 119-130.	1.4	21
188	Mechanisms underlying the cardiac antifibrotic effects of losartan metabolites. Scientific Reports, 2017, 7, 41865.	1.6	21
189	The Hypertensive Myocardium. Medical Clinics of North America, 2017, 101, 43-52.	1.1	21
190	Rationale of the FIBROTARGETS study designed to identify novel biomarkers of myocardial fibrosis. ESC Heart Failure, 2018, 5, 139-148.	1.4	21
191	Burden and challenges of heart failure in patients with chronic kidney disease. A call to action. Nefrologia, 2020, 40, 223-236.	0.2	21
192	Enhanced Na ⁺ -H ⁺ Exchanger Activity and NHE-1 mRNA Expression in Lymphocytes From Patients With Essential Hypertension. Hypertension, 1995, 25, 356-364.	1.3	21
193	The A1166C polymorphism of the AT1 receptor gene is associated with collagen type I synthesis and myocardial stiffness in hypertensives. Journal of Hypertension, 2003, 21, 2085-92.	0.3	21
194	Effects of Antihypertensive Agents on the Left Ventricle. American Journal of Cardiovascular Drugs, 2001, 1, 263-279.	1.0	20
195	Diagnosis and Treatment of Myocardial Fibrosis in Hypertensive Heart Disease. Circulation Journal, 2008, 72, A8-A12.	0.7	20
196	Altered degradation of extracellular matrix in myocardial remodelling: the growing role of cathepsins and cystatins. Cardiovascular Research, 2010, 87, 591-592.	1.8	20
197	Impact of acute hypertension transients on diastolic function in patients with heart failure with preserved ejection fraction. Cardiovascular Research, 2017, 113, 906-914.	1.8	20
198	Why Clinicians Should Care About theÂCardiac Interstitium. JACC: Cardiovascular Imaging, 2019, 12, 2305-2318.	2.3	20

#	Article	IF	Citations
199	Glucose-Dependent Insulinotropic Peptide in the High-Normal Range Is Associated With Increased Carotid Intima-Media Thickness. Diabetes Care, 2021, 44, 224-230.	4.3	20
200	Peroxisome Proliferator-Activated Receptor ?? and Hypertensive Heart Disease. Drugs, 2004, 64, 9-18.	4.9	19
201	Targeting the Cardiac Myofibroblast Secretome to Treat Myocardial Fibrosis in Heart Failure. Circulation: Heart Failure, 2016, 9, .	1.6	19
202	Plasma protein biomarkers and their association with mutually exclusive cardiovascular phenotypes: the FIBRO-TARGETS caseâ€“control analyses. Clinical Research in Cardiology, 2020, 109, 22-33.	1.5	19
203	A Biomarker of Myocardial Fibrosis Predicts Long-Term Response to Cardiac Resynchronization Therapy. Journal of the American College of Cardiology, 2006, 47, 2335-2337.	1.2	18
204	Role of Myocardial Collagen in Severe Aortic Stenosis With Preserved Ejection Fraction and Symptoms of Heart Failure. Revista Espanola De Cardiologia (English Ed), 2017, 70, 832-840.	0.4	18
205	Increased phagocytic NADPH oxidase activity associates with coronary artery calcification in asymptomatic men. Free Radical Research, 2017, 51, 389-396.	1.5	18
206	Glucose-dependent insulinotropic peptide and risk of cardiovascular events and mortality: a prospective study. Diabetologia, 2020, 63, 1043-1054.	2.9	18
207	Effects of Aldosterone on the Heart. Hypertension, 2008, 52, 462-464.	1.3	17
208	Association of cardiotrophin-1 with left ventricular systolic properties in asymptomatic hypertensive patients. Journal of Hypertension, 2013, 31, 587-594.	0.3	17
209	Atrial fibrillation and biomarkers of myocardial fibrosis in heart failure. Scandinavian Cardiovascular Journal, 2014, 48, 299-303.	0.4	17
210	Cardiac magnetic resonance-derived fibrosis, strain and molecular biomarkers of fibrosis in hypertensive heart disease. Journal of Hypertension, 2020, 38, 2036-2042.	0.3	17
211	Association of Phagocytic NADPH Oxidase Activity With Hypertensive Heart Disease. Hypertension, 2014, 63, 468-474.	1.3	16
212	Arterial Hypertension in Patients with Heart Failure. Heart Failure Clinics, 2014, 10, 233-242.	1.0	16
213	Aging and atrial fibrillation: a matter of fibrosis. Aging, 2019, 11, 9965-9966.	1.4	16
214	Biomarkerâ€based assessment of collagen crossâ€linking identifies patients at risk of heart failure more likely to benefit from spironolactone effects on left atrial remodelling. Insights from the <scp>HOMAGE</scp> clinical trial. European Journal of Heart Failure, 2022, 24, 321-331.	2.9	16
215	The unmet need of evidence-based therapy for patients with advanced chronic kidney disease and heart failure. CKJ: Clinical Kidney Journal, 2022, 15, 865-872.	1.4	16
216	Toward the biochemical assessment of myocardial fibrosis in hypertensive patients. American Journal of Cardiology, 1995, 76, 14D-17D.	0.7	15

#	Article	IF	Citations
217	TORAFIC study protocol: torasemide prolonged release versus furosemide in patients with chronic heart failure. Expert Review of Cardiovascular Therapy, 2009, 7, 897-904.	0.6	15
218	Epicardial Adipose Tissue in the General Middle-aged Population and Its Association With Metabolic Syndrome. Revista Espanola De Cardiologia (English Ed), 2017, 70, 254-260.	0.4	15
219	Heart failure in chronic kidney disease: the emerging role of myocardial fibrosis. Nephrology Dialysis Transplantation, 2022, 37, 817-824.	0.4	15
220	Does Chronic Kidney Disease Facilitate Malignant Myocardial Fibrosis in Heart Failure with Preserved Ejection Fraction of Hypertensive Origin?. Journal of Clinical Medicine, 2020, 9, 404.	1.0	15
221	Abnormal sympathetic and renal response to sodium restriction in compensated cirrhosis. Gastroenterology, 1991, 101, 1354-1360.	0.6	14
222	Quinapril Inhibits c-Myc Expression and Normalizes Smooth Muscle Cell Proliferation in Spontaneously Hypertensive Rats. American Journal of Hypertension, 1997, 10, 1147-1152.	1.0	14
223	Blockade of TGF-<mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML"><mml:mi mathvariant="bold-italic">Î²</mml:mi></mml:math>1 Signalling Inhibits Cardiac NADPH Oxidase Overactivity in Hypertensive Rats. Oxidative Medicine and Cellular Longevity, 2012, 2012, 1-8.	1.9	14
224	Decreased Nox4 levels in the myocardium of patients with aortic valve stenosis. Clinical Science, 2013, 125, 291-300.	1.8	14
225	Tissue availability of insulin-like growth factor I is inversely related to insulin resistance in essential hypertension. Journal of Hypertension, 1998, 16, 863-870.	0.3	13
226	Emerging role of matrix metalloproteinases in the pathophysiology of cardiac diseases. European Journal of Clinical Investigation, 2002, 32, 291-294.	1.7	13
227	New directions in the assessment and treatment of hypertensive heart disease. Current Opinion in Nephrology and Hypertension, 2005, 14, 428-434.	1.0	13
228	Insulin resistance determines phagocytic nicotinamide adenine dinucleotide phosphate oxidase overactivation in metabolic syndrome patients. Journal of Hypertension, 2009, 27, 1420-1430.	0.3	13
229	Is the tissue availability of circulating insulin-like growth factor I involved in organ damage and glucose regulation in hypertension?. Journal of Hypertension, 1997, 15, 1159-1165.	0.3	12
230	Obesity-related cardiac and vascular structural alterations: beyond blood pressure overload. Journal of Hypertension, 2009, 27, 1750-1752.	0.3	12
231	Potential role of microRNA-10b down-regulation in cardiomyocyte apoptosis in aortic stenosis patients. Clinical Science, 2016, 130, 2139-2149.	1.8	12
232	The need for a cardionephrology subspecialty. CKJ: Clinical Kidney Journal, 2021, 14, 1491-1494.	1.4	12
233	The association between markers of type I collagen synthesis and echocardiographic response to spironolactone in patients at risk of heart failure: findings from the HOMAGE trial. European Journal of Heart Failure, 2022, 24, 1559-1568.	2.9	12
234	Overexpression of human truncated peroxisome proliferator-activated receptor Â induces apoptosis in HL-1 cardiomyocytes. Cardiovascular Research, 2008, 79, 458-463.	1.8	11

#	Article	IF	Citations
235	Urinary proteomics in cardiovascular disease: Achievements, limits and hopes. Proteomics - Clinical Applications, 2011, 5, 222-232.	0.8	11
236	Characterization of biventricular alterations in myocardial (reverse) remodelling in aortic banding-induced chronic pressure overload. Scientific Reports, 2019, 9, 2956.	1.6	11
237	Identification of sexâ€specific biomarkers predicting newâ€onset heart failure. ESC Heart Failure, 2021, 8, 3512-3520.	1.4	11
238	Do microRNAs regulate myocardial fibrosis?. Nature Clinical Practice Cardiovascular Medicine, 2009, 6, 88-89.	3.3	10
239	Hypertrophic cardiomyopathy in myosin-binding protein C (MYBPC3) Icelandic founder mutation carriers. Open Heart, 2020, 7, e001220.	0.9	10
240	Serum and urinary biomarkers of collagen typeâ€I turnover predict prognosis in patients with heart failure. Clinical and Translational Medicine, 2021, 11, e267.	1.7	10
241	Intracerebroventricular Infusion of Sodium Chloride-Rich Artificial Cerebrospinal Fluid in Rats Induces Natriuresis and Releases An Inhibitor of Prostaglandin Synthesis. Clinical Science, 1984, 66, 621-624.	1.8	9
242	Uremia and Red Blood Cell Sodium Transport. Nephron, 1986, 43, 155-157.	0.9	9
243	Involvement of cardiomyocyte survivalâ€“apoptosis balance in hypertensive cardiac remodeling. Expert Review of Cardiovascular Therapy, 2003, 1, 293-307.	0.6	9
244	Targeting Î³-secretases protect against angiotensin II-induced cardiac hypertrophy. Journal of Hypertension, 2015, 33, 843-850.	0.3	9
245	Cooperative Cardiovascular Disease Research Network (RECAVA). Revista Espanola De Cardiologia (English Ed), 2008, 61, 58-65.	0.4	8
246	A translational approach to myocardial remodelling. Cardiovascular Research, 2008, 81, 409-411.	1.8	8
247	The angiotensin-converting enzyme insertion/deletion polymorphism is associated with phagocytic NADPH oxidase-dependent superoxide generation: potential implication in hypertension. Clinical Science, 2009, 116, 233-240.	1.8	8
248	Association of the peroxisome proliferator-activated receptor Î± gene L162V polymorphism with stage C heart failure. Journal of Hypertension, 2011, 29, 876-883.	0.3	8
249	PÃ©ptido similar al glucagÃ³n tipo 1 y supervivencia de la cÃ©lula cardiaca. Endocrinologia Y Nutricion: Organo De La Sociedad Espanola De Endocrinologia Y Nutricion, 2012, 59, 561-569.	0.8	8
250	Association of left atrium voltage amplitude and distribution with the risk of atrial fibrillation recurrence and evolution after pulmonary vein isolation: An ultrahighâ€density mapping study. Journal of Cardiovascular Electrophysiology, 2019, 30, 1231-1240.	0.8	8
251	Bases para la creaciÃ³n de las unidades clÃnicas cardiorrenales. Documento de consenso de los grupos de trabajo cardiorrenal de la SEC y la SEN. REC: CardioClinics, 2021, 56, 284-295.	0.1	8
252	La fibrosis intersticial miocÃ¡rdica en la era de la medicina de precisiÃ³n. El fenotipado basado en biomarcadores para un tratamiento personalizado. Revista Espanola De Cardiologia, 2020, 73, 248-254.	0.6	8

#	Article	IF	Citations
253	Current work in the cell biology of left ventricular hypertrophy. Current Opinion in Cardiology, 1994, 9, 512-519.	0.8	7
254	The influence of obesity on the assessment of carotid intimaâ€•media thickness. Journal of Clinical Ultrasound, 2012, 40, 479-485.	0.4	7
255	Compelling Benefit of Soluble Suppression of Tumorigenicityâ€2 in Postâ€“Myocardial Infarction Estimation of Risk: The Time Is Right for Its Routine Use in the Clinic. Journal of the American Heart Association, 2017, 6, .	1.6	7
256	Myocardial fibrosis as a matter of cell differentiation: opportunities for new antifibrotic strategies. European Heart Journal, 2019, 40, 979-981.	1.0	7
257	Reprint of â€œThe complex dynamics of myocardial interstitial fibrosis in heart failure. Focus on collagen cross-linkingâ€• Biochimica Et Biophysica Acta - Molecular Cell Research, 2020, 1867, 118521.	1.9	7
258	Burden and challenges of heart failure in patients with chronic kidney disease. A call to action. Nefrologia, 2020, 40, 223-236.	0.2	7
259	Generation of eight adjacent mutations in a single step using a site-directed mutagenesis kit. Clinical Chemistry and Laboratory Medicine, 2004, 42, 384-6.	1.4	6
260	Protective effect of the 1742(C/G) polymorphism of human cardiotrophin-1 against left ventricular hypertrophy in essential hypertension. Journal of Hypertension, 2010, 28, 2219-2226.	0.3	6
261	Transition to heart failure in hypertension: going to the heart of the matter. European Heart Journal, 2022, 43, 3332-3334.	1.0	6
262	Decreased excretion of nitrate and nitrite in essential hypertensives with renal vasoconstriction. Kidney International, 1998, 54, S10-S13.	2.6	5
263	Angiotensin II and the hypertensive heart. Journal of Hypertension, 2004, 22, 879-882.	0.3	5
264	The Role of Myocardial Collagen Network in Hypertensive Heart Disease. Current Hypertension Reviews, 2007, 3, 1-7.	0.5	5
265	Efecto vasodilatador de la ghrelina en la aorta de rata. Endocrinologia Y Nutricion: Organo De La Sociedad Espanola De Endocrinologia Y Nutricion, 2008, 55, 448-453.	0.8	5
266	Myocardial fibrosis in response to pressure overload: elucidating the contribution of tissue transglutaminase. Cardiovascular Research, 2017, 113, 841-843.	1.8	5
267	Circulating Biomarkers Predicting Longitudinal Changes in Left Ventricular Structure and Function in a General Population. Journal of the American Heart Association, 2019, 8, e010430.	1.6	5
268	Cardiorenal interaction and heart failure outcomes. A role for insulin-like growth factor binding protein 2?. Revista Espanola De Cardiologia (English Ed), 2020, 73, 835-843.	0.4	5
269	The A640G CYBA polymorphism associates with subclinical atherosclerosis in diabetes. Frontiers in Bioscience - Elite, 2011, E3, 1467-1474.	0.9	5
270	Genomics and Proteomics in Heart Failure Research. Revista Espanola De Cardiologia (English Ed), 2009, 62, 305-313.	0.4	4

#	Article	IF	Citations
271	Understanding the Role of CCN Matricellular Proteins in Myocardial Fibrosis â^—. Journal of the American College of Cardiology, 2016, 67, 1569-1571.	1.2	4
272	DPP-4 inhibition and blood pressure lowering in perspective. Journal of Hypertension, 2016, 34, 184-187.	0.3	4
273	Myocardial interstitial fibrosis in the era of precision medicine. Biomarker-based phenotyping for a personalized treatment. Revista Espanola De Cardiologia (English Ed), 2020, 73, 248-254.	0.4	4
274	Deficiency of Procollagen C-Proteinase Enhancer 1 in Mice has No Major Impact on Cardiac Collagen and Function Under Basal Conditions. Journal of Cardiovascular Pharmacology, 2021, 78, e703-e713.	0.8	4
275	A Fibrosis Biomarker Early Predicts Cardiotoxicity Due to Anthracycline-Based Breast Cancer Chemotherapy. Cancers, 2022, 14, 2941.	1.7	4
276	Corrigendum to â€˜Torasemide in chronic heart failure: results of the TORIC studyâ€™ [Eur. J. Heart Fail. 4 (2002) 507-513]. European Journal of Heart Failure, 2002, 4, 667-667.	2.9	3
277	Increased Fibroblast Growth Factor 23 in Heart Failure: Biomarker, Mechanism, or Both?. American Journal of Hypertension, 2019, 32, 15-17.	1.0	3
278	Developing the subspecialty of cardio-nephrology: The time has come. A position paper from the coordinating committee from the Working Group for Cardiorenal Medicine of the Spanish Society of Nephrology. Nefrologia, 2021, 41, 391-402.	0.2	3
279	Left Ventricular Hypertrophy and Treatment with Renin Angiotensin System Inhibition. , 2009, , 103-119.		3
280	Developing the subspecialty of cardio-nephrology: The time has come. A position paper from the coordinating committee from the Working Group for Cardiorenal Medicine of the Spanish Society of Nephrology. Nefrologia, 2021, 41, 391-402.	0.2	3
281	From cardiorenal syndromes to cardionephrology: a reflection of nephrologists on renocardiac syndromes. CKJ: Clinical Kidney Journal, 0, , .	1.4	3
282	Elevated Levels of Parathyroid Hormone in Essential Hypertensive Patients With Increased Erythrocyte Potassium Efflux. American Journal of Hypertension, 1991, 4, 714-718.	1.0	2
283	Hypertensive Heart Disease. , 2007, , 621-631.		2
284	Contribution of circulating biomarkers to unravel the role of extracellular matrix in hypertensive cardiac remodelling. Journal of Hypertension, 2012, 30, 34-37.	0.3	2
285	El tratamiento de la insuficiencia cardÃaca con fracciÃ³n de eyecciÃ³n preservada. Un problema sin resolver. Revista Clinica Espanola, 2015, 215, 320-321.	0.2	2
286	The renal immune-inflammatory component of arterial hypertension: emerging therapeutic strategies. Cardiovascular Research, 2019, 115, 696-698.	1.8	2
287	Is the Deficiency of the Long Isoform of Cellular FLICE-Inhibitory Protein Involved in Myocardial Remodeling?. Hypertension, 2010, 56, 1045-1046.	1.3	1
288	Towards the molecular diagnosis of hypertensive heart disease?. Journal of Hypertension, 2011, 29, 660-662.	0.3	1

#	Article	IF	Citations
289	Cooperative Research in Biomedicine. Spain's Cardiovascular Network, Red de InvestigaciÃ³n Cardiovascular. Revista Espanola De Cardiologia (English Ed), 2014, 67, 254-258.	0.4	1
290	Unraveling New Mechanisms of Renal Fibrosis With Potential Therapeutic Implications. Hypertension, 2018, 72, 277-278.	1.3	1
291	Heart failure-related skeletal myopathy. Potential involvement of myokines. Revista Espanola De Cardiologia (English Ed), 2021, 74, 1008-1012.	0.4	1
292	Reninâ€“Angiotensinâ€“Aldosterone System and Cardiomyocyte Apoptosis in Hypertensive Heart Disease. , 2009, , 143-150.		1
293	Serum Markers of Fibrillar Collagen Metabolism in Cardiac Diseases. , 2005, , 101-113.		0
294	Highlights from International Congress. High Blood Pressure and Cardiovascular Prevention, 2006, 13, 61-72.	1.0	0
295	Angiotensin II and Myocardial Fibrosis, Clinical Implications. , 2006, , 193-213.		0
296	Avances en cardiopatÃa hipertensiva. Mecanismos de remodelado implicados en la transiciÃ³n de la hipertrofia a la insuficiencia cardiaca. Revista Espanola De Cardiologia Suplementos, 2007, 7, 14F-21F.	0.2	0
297	Mechanical dyssynchrony: another mechanism of left ventricular dysfunction in hypertension?. Journal of Hypertension, 2008, 26, 399-402.	0.3	0
298	Corrigendum to â€œPreliminary characterisation of the promoter of the human p22phoxgene: Identification of a new polymorphism associated with hypertensionâ€•[FEBS Lett. 542 (2003) 27-31]. FEBS Letters, 2010, 584, 4709-4709.	1.3	0
299	Altered regulation of the epithelial sodium channel in hypertension. From genes to therapeutics. Journal of Hypertension, 2011, 29, 204-206.	0.3	0
300	Aspectos emergentes del sistema renina-angiotensina en la diabetes: Â¿cÃ³mo abordar su traslaciÃ³n a la clÃnica?. Revista Espanola De Cardiologia Suplementos, 2011, 11, 37-41.	0.2	0
301	Angiotensin II and Myocardial Remodeling: Do Macrophages Hold the Key?. American Journal of Hypertension, 2011, 24, 626-627.	1.0	0
302	What is on the horizon for improved treatments for acutely decompensated heart failure?. European Heart Journal Supplements, 2016, 18, G33-G42.	0.0	0
303	Biomarkers of Cardiovascular Disease. , 2019, , 319-330.		0
304	MO734CONTRIBUTION OF SOLUBLE ST2 TO THE EFFECT OF RIGHT VENTRICULAR DYSFUNCTION ON MORTALITY IN HEMODIALYSIS PATIENTS. Nephrology Dialysis Transplantation, 2021, 36, .	0.4	0
305	MiopatÃa esquelÃ©tica en la insuficiencia cardiaca. ImplicaciÃ³n potencial de las miocinas. Revista Espanola De Cardiologia, 2021, 74, 1009-1009.	0.6	0
306	Reply. Journal of the American College of Cardiology, 2018, 71, 2984-2985.	1.2	0

#	Article	IF	Citations
307	Remodeling in Hypertensive Heart Disease: Role of the Renin-Angiotensin-Aldosterone System. , 2006, , 177-189.		0
308	MO747: Endotrophin Levels are Extremely Elevated in Dialysis Patients with Heart Failure with Preserved Ejection Fraction (HFPEF) and are Influenced by Background Treatment with Diuretics and ARBS/ACEI. Nephrology Dialysis Transplantation, 2022, 37, .	0.4	0